Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Average Target Price of $71.15 According to Analysts

Xenon Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $71.15.

XENE has been the topic of several analyst reports. Wells Fargo & Company dropped their target price on Xenon Pharmaceuticals from $69.00 to $64.00 and set an "overweight" rating on the stock in a report on Friday, September 18th. Deutsche Bank downgraded Xenon Pharmaceuticals from a "buy" rating to a "hold" rating and reduced their price target for the company from $90.00 to $46.00 in a report on Friday, September 18th. Wall Street Zen lowered Xenon Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Sunday, October 11th. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $78.00 to $60.00 and set a "buy" rating for the company in a research report on Friday, September 18th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, September 28th.

Read Our Latest Stock Report on Xenon Pharmaceuticals

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $37.04 on Friday. The firm has a 50 day moving average price of $39.02 and a 200-day moving average price of $52.04. Xenon Pharmaceuticals has a 52-week low of $33.38 and a 52-week high of $72.66. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -7.88 and a beta of 0.11.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.02. As a group, sell-side analysts forecast that Xenon Pharmaceuticals will post -4.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CFO Thomas Patrick Kelly purchased 15,000 shares of the business's stock in a transaction dated Wednesday, September 30th. The shares were purchased at an average price of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the acquisition, the chief financial officer directly owned 15,000 shares in the company, valued at $559,800. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ian Mortimer purchased 30,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Wednesday, September 30th. The shares were purchased at an average cost of $37.38 per share, with a total value of $1,121,400.00. Following the transaction, the chief executive officer directly owned 49,923 shares of the company's stock, valued at $1,866,121.74. This represents a 150.58% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 2.91% of the stock is owned by company insiders.

Institutional Trading of Xenon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at $6,813,000. BlackRock Inc. purchased a new position in Xenon Pharmaceuticals in the 2nd quarter worth about $454,057,000. Engineers Gate Manager LP raised its position in Xenon Pharmaceuticals by 566.8% in the 2nd quarter. Engineers Gate Manager LP now owns 62,183 shares of the biopharmaceutical company's stock worth $3,753,000 after buying an additional 52,857 shares during the last quarter. Bank of New York Mellon Corp raised its position in Xenon Pharmaceuticals by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company's stock worth $23,035,000 after buying an additional 8,980 shares during the last quarter. Finally, Man Group plc purchased a new position in Xenon Pharmaceuticals in the 2nd quarter worth about $18,749,000. Institutional investors own 95.45% of the company's stock.

About Xenon Pharmaceuticals

(Get Free Report)

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company's research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.

Further Reading

Analyst Recommendations for Xenon Pharmaceuticals (NASDAQ:XENE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?

Before you consider Xenon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.

While Xenon Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines